Benzosceptrin C 

Benzosceptrin C is an inhibitor for PD-L1, which promotes programmed cell death ligand (PD-L1) degradation in a lysosomal pathway, enhances the cytotoxicity of T-cells and exhibits antitumor activity^[1].

Benzosceptrin C (0-10 μM) inhibits PD-L1 expression in CRC cancer cells, enhances T-cell cytotoxicity through PD-L1 checkpoints disruption, and inhibits proliferations of CRC cancer cells RKO and HCT116^[1].
Benzosceptrin C (0-10 μM) blocks the palmitoylation of PD-L1 by inhibiting DHHC3, thus promotes the lysosomal degradation of PD-L1, blocks the direct interaction of PD-L1 and PD-1 and exert an immune antitumor effect^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Benzosceptrin C (5-50 mg/kg/day, i.p. for 16 days) inhibits tumor growth in MC38 xenograft C57BL/6 mice through activation of tumor-infiltrating T cells and induction of apoptosis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

774.06

C₂₂H₁₈Br₄N₁₀O₂

1204605-36-6

O=C(C1=CC(Br)=C(N1)Br)NC[C@H]2C3=C(NC(N)=N4)C4=C(N=C(N5)N)C5=C3[C@@H]2CNC(C6=CC(Br)=C(N6)Br)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wang Q, et al., Benzosceptrin C induces lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting DHHC3. Cell Rep Med. 2024 Feb 20;5(2):101357.  [Content Brief]